DAIC

FEBRUARY 27, 2024

milla1cf Tue, 02/27/2024 - 17:29 February 27, 2024 — Aria CV, Inc , a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St.

Pulmonary 110

Pulmonary Hypertension Heart Failure Blood Pressure 110

DAIC

MAY 8, 2024

Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH).

Ultrasound 115

Ultrasound Pulmonary Research Hypertension 115

Heart BMJ

AUGUST 26, 2024

LEARNING OBJECTIVES Review the diagnostic pathway for pulmonary arterial hypertension (PAH) in congenital heart disease (CHD). Understand and interpret right heart catheterisation data in pulmonary hypertension related to CHD. Recognise the typical presentation of PAH in patients with CHD.

Congenital Heart Disease 52

Congenital Heart Disease Congenital Pulmonary Hypertension 52

Journal of Clinical Investigation - Cardiology

FEBRUARY 1, 2024

Pulmonary arterial hypertension (PAH) is a devastating and progressive disease with limited treatment options. Endothelial haploinsufficiency of RAB7 caused spontaneous pulmonary hypertension (PH) in mice. Here, we explored the role of RAB7 in endothelial cell (EC) function and lung vascular homeostasis.

Pulmonary 98

Pulmonary Hypertension 98

DAIC

JULY 10, 2024

“This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven by underlying disruption in serotonin signaling like pulmonary hypertension,” said Laxminarayan Bhat, Ph.D. Founder, President, and CEO. Brilaroxazine has already received Orphan Drug Designation by the U.S.

Pulmonary 111

Pulmonary Hypertension Pharmacology Biomarkers 111

DAIC

DECEMBER 13, 2023

Pulmonary arterial hypertension, a form of high blood pressure that occurs in the lungs, is a target of research by Cedars-Sinai investigators. Pulmonary arterial hypertension is a rare disease, affecting fewer than 100 people per million. Siegel Family Foundation Distinguished Professor and senior author of the study. “We

Pulmonary 105

Pulmonary Hypertension Blood Pressure Research 105

Frontiers in Cardiovascular Medicine

JULY 24, 2024

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure.

Pulmonary 52

Pulmonary Hypertension Angioplasty Pharmacology 52

Medical Xpress - Cardiology

MAY 2, 2024

This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading to chronic lung disease, heart failure and death. Blood vessels in the lungs aren't like the others in the body.

Pulmonary 75

Pulmonary Hypertension Heart Failure 75

Journal of Cardiothoracic Surgery

AUGUST 20, 2024

This research evaluates the effect of balloon pulmonary angioplasty (BPA) on cardiac electrophysiological changes in patients with chronic thromboembolic pulmonary hypertension (CTEPH).

Angioplasty 52

Angioplasty Pulmonary Hypertension Electrophysiology 52

All About Cardiovascular System and Disorders

APRIL 7, 2024

Transcript of the video: Now we will discuss a chest X-ray showing antler sign in pulmonary venous hypertension. So, the shape of the upper lobe vessels in venous hypertension, pulmonary venous hypertension, will be resembling the antlers of the stag. You can see the antlers here.

Pulmonary 52

Pulmonary Hypertension General Cardiology 52

Medical Xpress - Cardiology

JULY 8, 2024

Pulmonary hypertension is a very serious disease that leads to heart failure and death in many patients.

Pulmonary 88

Pulmonary Hypertension Physiology Heart Failure 88

Circulation

NOVEMBER 11, 2024

Introduction:Obesity is rising in prevalence worldwide and co-exists in patients with group 1 pulmonary hypertension (PH). Despite having group 1 PH, pulmonary capillary wedge pressure (PCWP) was higher with obesity (13.8 ± 6.3 0002) and lower pulmonary vascular resistance (PVR, 7.9 ± 5.2 vs 10.4 ± 6.5 vs 4.5 ± 1.8

Obesity 40

Obesity Pulmonary Hypertension Diabetes 40

American College of Cardiology

JUNE 10, 2024

What is the comparative effectiveness of therapies targeting the different treatment pathways in pulmonary arterial hypertension (PAH)?

Pulmonary 52

Pulmonary Hypertension Article 52

Heart BMJ

AUGUST 26, 2024

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complex pulmonary vascular disorder that involves major vessel and microvascular disease components. Fibrotic obstructions resulting from unresolved pulmonary emboli constitute the major vessel disease component.

Pulmonary 52

Pulmonary Hypertension Biomarkers Angioplasty 52

Science Daily - Heart Disease

DECEMBER 13, 2023

Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, a form of high blood pressure that occurs in the blood vessels of the lungs and typically affects middle-aged women, according to a new study.

Pulmonary 103

Pulmonary Hypertension Blood Pressure 103

The British Journal of Cardiology

JANUARY 16, 2024

Pulmonary hypertension is a rare disease, associated with a significant deterioration in quality of life, usually not curable and with an ominous prognosis. We present the case of a patient diagnosed with precapillary component pulmonary hypertension, with the finding of an arteriovenous fistula at the peripheral level.

Pulmonary 52

Pulmonary Hypertension Quality of Life Article 52

American College of Cardiology

AUGUST 7, 2024

In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.

Obesity 61

Obesity Pulmonary Hypertension TAVR 61

Medical Xpress - Cardiology

MARCH 29, 2024

Food and Drug Administration has approved Winrevair (sotatercept-csrk) as an injectable treatment for pulmonary arterial hypertension (PAH) in adults.

Pulmonary 77

Pulmonary Hypertension 77

Circulation

NOVEMBER 11, 2024

Introduction:Inflammation is a key driver in the development of pulmonary arterial hypertension (PAH). The pulmonary vasculature was evaluated histologically. Circulation, Volume 150, Issue Suppl_1 , Page A4142839-A4142839, November 12, 2024. The gut microbiome is a complex ecosystem consisting of trillions of organisms, 0.1%

Pulmonary 40

Pulmonary Hypertension Innovation Exercise 40

Circulation

NOVEMBER 11, 2024

Rationale:Pulmonary arterial hypertension (PAH) is a devastating disease characterized by a progressive rise in pulmonary vascular resistance and occlusive vascular remodeling, leading to right heart failure and premature death. Endothelial cell (EC) damage and dysfunction is a key feature of pulmonary vascular remodeling and PAH.

Pulmonary 40

Pulmonary Hypertension Heart Failure Circulation 40

DAIC

MAY 6, 2024

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

American College of Cardiology

JUNE 28, 2024

For the treatment of pulmonary arterial hypertension (PAH), is sildenafil 80 mg TID noninferior to sildenafil 5 mg TID for all-cause mortality?

Pulmonary 57

Pulmonary Hypertension Article 57

Medical Xpress - Cardiology

JANUARY 19, 2024

A research team has discovered a possible therapeutic target for pulmonary hypertension.

Pulmonary 101

Pulmonary Hypertension Cardiac Function Research 101

Open Heart

MAY 7, 2024

Background The treatment of pulmonary hypertension (PH) has improved rapidly in recent decades. Treatment escalation was defined as an additional pulmonary arterial hypertension (PAH) drug, pulmonary endarterectomy, percutaneous balloon angioplasty or bilateral lung transplantation.

Heart Monitor 52

Heart Monitor Pulmonary Hypertension Angioplasty 52

Medical Xpress - Cardiology

DECEMBER 13, 2023

Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, a form of high blood pressure that occurs in the blood vessels of the lungs and typically affects middle-aged women, according to a study led by Cedars-Sinai investigators.

Pulmonary 85

Pulmonary Hypertension Blood Pressure 85

HCPLive

MARCH 22, 2024

The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.

Pulmonary 64

Pulmonary Hypertension 64

American College of Cardiology

DECEMBER 14, 2023

What is the impact on prognosis of the 2022 ESC/ERS pulmonary hypertension (PH) guidelines on the new redefined hemodynamic threshold for the diagnosis of precapillary PH?

Pulmonary 49

Pulmonary Hypertension Outcomes Article 49

Circulation

MARCH 7, 2024

Balloon pulmonary angioplasty continues to gain traction as a treatment option for patients with chronic thromboembolic pulmonary disease with and without pulmonary hypertension. Not surprisingly, chronic thromboembolic pulmonary hypertension centers are rapidly initiating balloon pulmonary angioplasty programs.

Angioplasty 45

Angioplasty Pulmonary Hypertension Document 45

Circulation

NOVEMBER 11, 2024

Objective:Pulmonary Arterial Hypertension (PAH) is a fatal disease with high mortality rates and late diagnosis, currently lacking complete cure. Metabolic abnormalities play a crucial role in the pathophysiological process of pulmonary vascular remodeling. ng/ml; idiopathic pulmonary arterial hypertension group: 5.28 ± 0.77

Pulmonary 40

Pulmonary Hypertension Heart Failure Circulation 40

Circulation

NOVEMBER 11, 2024

Background:Primary pulmonary arterial hypertension (PAH) is a disease affecting young subjects. Circulation, Volume 150, Issue Suppl_1 , Page A4117657-A4117657, November 12, 2024. It has very poor prognosis and optimal treatment is not available.

Pulmonary 40

Pulmonary Hypertension Blood Pressure Pharmacology 40

American College of Cardiology

JUNE 12, 2024

In this week’s View, Dr. Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension.

Pulmonary 57

Pulmonary Hypertension Outcomes Article 57

American College of Cardiology

JANUARY 23, 2024

The goal of the A DUE trial was to compare the safety and efficacy of macitentan/tadalafil combination therapy versus macitentan and tadalafil monotherapies in patients with pulmonary arterial hypertension (PAH).

Pulmonary 52

Pulmonary Hypertension Article 52

Frontiers in Cardiovascular Medicine

MAY 8, 2024

Patients with pulmonary hypertension associated with a left-right shunt include a wide spectrum of pathophysiological substrates, ranging from those characterized by pulmonary over-circulation to those with advanced pulmonary vascular disease.

Congenital Heart Disease 52

Congenital Heart Disease Pulmonary Hypertension Congenital 52

Circulation

NOVEMBER 11, 2024

Rationale:Previously we identified a mouse modelTie2Cre-mediated disruption ofEgln1of Pulmonary arterial hypertension (PAH) with progressive obliterative vascular remodeling including vascular occlusion and plexiform-like lesions and right heart failure. RVSP and RV/(LV+S) ratio were measured.

Pulmonary 40

Pulmonary Hypertension Heart Failure Circulation 40

Med Page Today

DECEMBER 12, 2023

(MedPage Today) -- Stable patients with pulmonary vascular disease (PVD) tolerated travel to high altitudes fairly well with frequent monitoring and supplemental oxygen therapy provided as necessary, a field study found. Despite the perceived.

Pulmonary 101

Pulmonary Hypertension 101

All About Cardiovascular System and Disorders

FEBRUARY 2, 2024

Biatrial enlargement with pulmonary venous hypertension

Pulmonary 52

Pulmonary Hypertension General Cardiology 52

Frontiers in Cardiovascular Medicine

NOVEMBER 17, 2024

BackgroundAllergy to iodine contrast agents has long been a contraindication for balloon pulmonary angioplasty (BPA). The second BPA procedure was successfully performed using the fusion of previous pulmonary artery CTA images and real-time fluoroscopy images.

Angioplasty 52

Angioplasty Pulmonary Technology Hypertension 52